Supernus and Adamas have entered into a definitive merger agreement under which Supernus will acquire all of the outstanding shares of common stock of Adamas for $8.10 per share in cash. ADMS stock soars 71% today right after the news. It is trading today at $7.90.
The first CVR is payable upon achieving sales of $150 million in four successive quarters between closing and the End of 2024. The second one is payable upon achieving sales of $225 million in four quarters between closing and the End of 2025.
The company will receive two products: the GOCOVRI extended-release capsules and the Osmofix ER tablets. These products are used by patients with active Parkinson’s disease and other related conditions. Jack Khattar, Supernus Pharmaceuticals’ President and CEO, said that the acquisition of Adamas Pharmaceuticals will allow the company to expand its portfolio of products targeting central nervous system diseases.